The Award includes a monetary award and memento, which will be presented at the 2020 ISBRA Early Career Investigator Award Symposium during the 2020 ISBRA/RSA Conference, June 20-24, 2020, in New Orleans, Louisiana, USA. In addition, award recipients will be acknowledged at the ISBRA/RSA Conference Closing Ceremony. Therefore, if you are selected as an award recipient by the ISBRA Membership Committee, you will be required to attend the 2020 Conference. Recipients must be an ISBRA member. If you are not currently an ISBRA member, your membership application (https://www.isbra.com/membership/) must be received by January 1, 2020. Awards will be limited to early career investigators (either PhD or MD students or young post-docs/physicians) (see application details below). All awardees will give a brief oral presentation at the ISBRA Early Career Investigator Award Symposium. Award recipients will be notified by March 1, 2020.
We are pleased to announce the Call for Nominations for the 2020 ISBRA Tabakoff Award to be presented at the joint ISBRA/RSA Conference June 20-24, 2020, in New Orleans, Louisiana, USA! ISBRA will support this award for excellence in research, which includes all aspects of biomedical research on alcoholism (basic and preclinical, translational and clinical work, genetics, and epidemiology), with a monetary award and a nice memento. The awardee will also be invited to present a plenary lecture at the joint ISBRA/RSA Conference in June 2020.
For over 40 years, Hiromasa Ishii MD, PhD, Professor Emeritus, Keio University, was an outstanding investigator in the fields of alcohol-induced organ diseases, hepatic metabolism and gastroenterology. With his death on 31 May 2010, from complications of myocardial infarction, his large family of colleagues and friends lost a most productive and fascinating leader.…
…Dr Ishii started his career with an MD from Keio University School of Medicine, and a PhD in gastroenterology and hepatology from Keio University. He then pursued his postdoctoral training with Dr Charles S. Lieber at Bronx VA Medical Center and at Mount Sinai School of Medicine in New York City, during this time, where he began his deep involvement in his lifelong research theme alcohol-mediated liver and pancreatic disease, under his tutelage. Dr Ishii, in collaboration with Dr. Lieber, clarified the role of a new microsomal pathway of ethanol metabolism, then known as microsomal ethanol oxidizing sysytem (MEOS) (now accepted as cytochrome P450 [CYP]2E1). Dr Ishii proved biochemically and immunohistochemically that chronic alcohol consumption stimulated adaptive proliferation of the smooth endoplasmic reticulum in hepatocytes, and this increases metabolism of ethanol and other drugs, thereby explaining both tolerance to ethanol and increased hepatotoxicity of various drugs, anesthetics, and carcinogens. Several important medications, such as anticoagulants and sedatives, show decreased effectiveness in alcoholics because of this increased microsomal CYP2E1 activity. This remarkable finding is a fine tribute to his work as an investigator.
ISBRA commemorates Dr. Ishii's life and career by presenting an award in his name every two years at the ISBRA Congress.